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Abstract
Background: This study examined whether a perioperative regimen of pregabalin added to celecoxib improved pain scores 
and functional outcomes postdischarge up to 3 months after total hip arthroplasty (primary outcome) and acute postoperative 
pain and adverse effects (secondary outcomes).
Methods: One hundred and eighty-four patients were enrolled in a randomized, double-blind, placebo-controlled study. Two 
hours before receiving a spinal anaesthetic and undergoing surgery, patients received celecoxib 400 mg p.o. and were randomly 
assigned to receive either pregabalin 150 mg p.o. or placebo p.o. After surgery, patients received pregabalin 75 mg or placebo 
twice daily in hospital and for 7 days after discharge. Patients also received celecoxib 200 mg every 12 h for 72 h and morphine i.v. 
patient-controlled analgesia for 24 h. Pain and function were assessed at baseline, 6 weeks, and 3 months after surgery. 
Results: There was no difference between groups in physical function or incidence and intensity of chronic pain 3 months 
after total hip arthroplasty. The pregabalin group used less morphine [mean (): 39.85 (28.1) mg] than the placebo group [54.01 
(31.2) mg] in the first 24 h after surgery (P<0.01). Pain scores were significantly lower in the pregabalin group vs the placebo 
group on days 1–7 after hospital discharge, and the pregabalin group required less adjunctive opioid medication (Percocet) 1 
week after hospital discharge (P<0.05).
Conclusions: Perioperative administration of pregabalin did not improve pain or physical function at 6 weeks or 3 months 
after total hip arthroplasty. Perioperative administration of pregabalin decreased opioid consumption in hospital and reduced 
daily pain scores and adjunct opioid consumption for 1 week after discharge.
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Editor’s key points
• Maximizing functional recovery after hip arthoplasty, with
minimal pain, is an important aim. Pregablin has been used
in the perioperative period,with someevidence of acute an-
algesic benefit.
• Pregabalin reduced pain and analgesia for 1 week after sur-
gery but not longer.
• Further studies are needed of pregabalin in acute, subacute,
and chronic pain after surgery.
Total hip arthroplasty (THA) is a surgical procedure indicated in
themanagement of severe, degenerative osteoarthritis and prox-
imal femoral fractures. More than 300 000 THAs are performed
each year in the USA,1 with this number expected to double by
2025 and quadruple by 2040.2 Although intended to reduce
pain, improve function, and benefit quality of life, THAs are asso-
ciated with moderate-to-severe postoperative pain, which can
persist and evolve into chronic pain.3
Themanagement of acute pain after THA has been well stud-
ied and involves multimodal analgesia, including opioids and
other adjuncts. This serves well in hospital; however, post-
operative pain in surgical patients after hospital discharge re-
mains a significant challenge. A recent national study in the
USA revealed that 80% of patients experience acute pain after
surgery and that this pain was more common after discharge
than before.4 Additional evidence reveals that postoperative
pain for surgical patients can persist for 2–6weeks after discharge
from hospital and can limit participation in daily activities.5–7
Furthermore, it has been shown that poorly controlled post-
operative pain can lead to the development of chronic pain.8
Pregabalin is a structural analogue of γ-aminobutyric acid
(GABA) that acts on the α2δ subunit of voltage-dependent calcium
channels. It was initially introduced in 2004 as an anticonvul-
sant.9 Compared with its predecessor, gabapentin, pregabalin
possesses superior oral absorption and bioavailability.10 More re-
cently, like gabapentin, pregabalin has attractedmuch interest as
an adjunct in themanagement of neuropathic and postoperative
pain. This has been reflected in severalmeta-analyses suggesting
that pregabalin reduces postoperative opioid consumption and
postoperative nausea and vomiting.11 12 There is also the sugges-
tion that perioperative pregabalin may prevent the development
of chronic postsurgical pain.13 The literature regarding this, how-
ever, is equivocal, as pregabalin has been shown to reduce acute
postoperative pain and opioid consumption in spine,14 15
breast,16 17 and gynaecological procedures,18 19 but not in laparo-
scopic cholecystectomies,20 ankle surgery,21 or cosmetic sur-
gery.22 Furthermore, perioperative pregabalin has also been
shown to reduce chronic pain and improve functioning in total
knee arthroplasty23 and lumbar discectomy patients.24 Others
have pointed to a publication bias highlighting unpublished
data that failed to show a difference between pregabalin and pla-
cebo for the prevention of chronic postsurgical pain.25
The literature on the effects of pregabalin for THA is sparse.
A prospective, double-blind, randomized, placebo-controlled
study involving 120 patients demonstrated that a preoperative
dose of 300 mg of pregabalin reduced postoperative morphine
requirements compared with placebo.26 In addition, compared
with patient-controlled analgesia usingmorphine alone, amulti-
modal analgesic regimen that included pregabalin 75 mg before
surgery and pregabalin 75 mg twice daily (BID) for 48 h produced
equal levels of satisfactory pain control and fewer adverse ef-
fects.27 However, there is a lack of consensus regarding the appro-
priate dose or timing of pregabalin administration required to
improve acute and postdischarge postoperative pain and physical
functioning after surgery.
We conducted this randomized, double-blind, placebo-
controlled study to examine whether the addition of pregabalin
to our perioperative THA analgesic regimen in the perioperative
period and for 7 days after discharge improves pain and function-
al outcomes up to 3 months after surgery.
Methods
Patient sample and recruitment procedures
The study was approved by the Sunnybrook Health Science
Centre Research Ethics Board, and all patients gave informed,
written consent to participate. Patient’s between the ages of
18 and 80 yr with an ASA physical status score of I, II, or III under-
going primary total hip arthroplasty were eligible to participate.
Patients were not eligible if they had a known allergy to any of
the medications being used, a history of drug or alcohol abuse,
a history of being on chronic pain medications (e.g. slow-release
preparations of opioids), short-acting opioids at a dose greater
than 30 mg day−1 of oral morphine equivalents, anticonvulsant
medications, rheumatoid arthritis, a psychiatric disorder, a
history of diabetes with impaired renal function (creatinine
>104 μmol/L), a BMI of >40 kg m−2, or were unable or unwilling
to use patient-controlled analgesia (PCA).
All subjects were screened in order to ensure eligibility, and
patients were recruited at the preoperative assessment approxi-
mately 1–2weeks before surgery. At that time, the study protocol,
use of the PCA pump, and an 11-point numerical rating scale
(NRS) for pain (0=‘no pain’ and 10=‘worst pain possible pain’)
were explained. Baseline physical function measures and psy-
chosocial questionnaires were completed at the preoperative as-
sessment or on the morning of surgery before the procedure.
Drug preparation, dispensing, and randomization
Pregabalin capsules were provided by Pfizer Canada Inc., and pla-
cebo medications were encapsulated in identically coloured gel-
atin capsules and packaged in identical individual blister packs
by the Sunnybrook Health Sciences Centre Investigational Phar-
macy in order to maintain double-blind conditions. The placebo
capsules contained a mixture of 50% cellulose and 50% lactose
monohydrate. A computer-generated randomization schedule
was used to assign patients at random, in blocks of six, to one
of the two treatment groups. The schedule was created by the
hospital investigational pharmacy, which was otherwise not in-
volved in the clinical care of the patients or in the conduct of the
trial. The randomization schedulewas kept in the pharmacy, and
none of the investigators had access to it. The pharmacy dis-
pensed the capsules according to the randomization schedule
when the investigators informed them that a patient hadbeen re-
cruited into the trial. Researchers were also blind to drug assign-
ment during data analysis.
Pre- and intraoperative anaesthesia care
Standardpractice at the SunnybrookHollandOrthopedic andArth-
ritic Centre is for patients to continue taking celecoxib until sur-
gery. On the day of surgery, all patients received celecoxib 400 mg
p.o., 2 h before surgery. Patientswere randomly assigned to receive
either pregabalin 150mg p.o. or placebo p.o. at the same time they
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received the celecoxib. Two hours after ingestion of the study
medication, patients were transferred to the regional anaesthesia
block area, where an i.v. cannula was inserted and an i.v. infusion
of lactated Ringer’s solution was started at a rate of 100 ml h−1.
Blood pressure, ECG, and oximetry were monitored. Midazolam
1–3 mg i.v. was administered. Spinal anaesthesia was performed
in the lateral decubitus or sitting position using a 25 gauge Whi-
tacre needle. Hypobaric bupivacaine 0.5% (10 ml) with fentanyl
10 μg was injected. In the operating room, sedation was provided
with propofol infusion (25–100 μg kg−1 min−1 i.v.) until the end of
surgery. Surgical techniques were standardized at the Holland
Orthopaedic and Arthritic Centre. The attending anaesthetist was
not involved in the patients’ postoperative evaluation.
Postoperative anaesthesia care
Patients were asked to record their resting and movement-
evoked pain intensity using a 10 cm NRS, commencing in the
postanaesthetic care unit after surgery upon being given the i.v.
PCA morphine device, and continuing every 6 h for the next 24 h.
The PCA pump was set to deliver morphine 1 mg on demand with
a 5 min lockout interval and no background infusion. All patients
were instructed to maintain their pain intensity at less than 4/10
on the NRS. If the NRS pain score at rest was rated 5 cm or greater
on two consecutive 4 hourly assessments, the dose of i.v. PCAmor-
phinewas increased to 1.5 mg per demand. Once the patients’ pain
was reported as ≤4/10, the i.v. PCA pump setting returned to 1.0 mg
per demand. At each time point when pain wasmeasured, patients
were also assessed for the presence of nausea, vomiting, pruritus,
and the severity of sedation [0=alert, 1=mildly sedated (occasionally
drowsy, easy to arouse), 2=moderately sedated (frequently drowsy,
easy to arouse), 3=severely sedated (somnolent, difficult to arouse),
S=normal sleep, easy to arouse].
Upon discharge from the postanaesthesia care unit, all pa-
tients received a standard postoperative regimen of celecoxib
200 mg every 12 h and a morphine i.v. PCA device for 24 h.
Patients received either pregabalin 75 mg BID or placebo BID
according to the preoperative randomization allocation, starting
8 h after the preoperative dose and continuing throughout their
hospital stay and for 7 days after discharge. Oxycontin 5 mg
every 8 h was started at 08.00 h on the morning after surgery
to facilitate the termination of PCA morphine at 24 h. After
surgery, all patients were managed using a standardized hip ar-
throplasty care pathway that included daily physiotherapy treat-
ment. Patients were permitted to be fully weight-bearing and
participated in a progressive programme of range of motion,
strengthening exercises, and functional training.
The Departments of Anaesthesiology, Orthopaedic Surgery,
Rehabilitation Science, and Psychology collaborated on the pre-
sent project; each unit was instrumental in selecting the various
outcome measures and in ensuring that appropriately qualified
people collected the data. Fully qualified and trained phy-
siotherapists at the Holland Orthopedic and Arthritic Centre col-
lected the physiotherapy data, and our study coordinators
(certified RNs and research coordinators) were responsible for
the collection of pain data and follow-up questionnaire data.
Blinding was maintained throughout the study until the code
was broken upon the completion of our statistical analysis.
Follow-up data collection at 7 days, 6 weeks, 
and 3 months after discharge
Patients were discharged home with a diary to make note of ad-
verse reactions that might be a result of the study medication.
Every day for up to 7 days after the patient was discharged from
hospital, the research coordinator followed up with the patient
via a telephone call to inquire about pain intensity, physical func-
tion, and adverse reactions. Patients were expected to return to
the Holland Arthritic and Orthopedic Centre at 6 weeks and 3
months, at which time the battery of physical function tests
and psychological questionnaires were re-administered.
Questionnaires
Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC LK3.1)28 29 is a 24-item Likert scale that assesses the ex-
tent towhich patientswith knee or hip osteoarthritis, or both, ex-
perience pain, stiffness, and physical functional impairment.
The Hospital Anxiety and Depression Scale (HADS)30 is a 14-
item Likert scale that assesses symptoms of depression (7-item
subscale) and anxiety (7-item subscale). Both questionnaires
were administered at baseline, postoperative day (POD) 4, 6
weeks, and 3 months after THA. When administered on POD 4,
patients were asked to report how they had been feeling while
in hospital.
Functional outcomes
The timed get-up-and-go test, the stair test, and the 6 min walk 
test were used to evaluate functional performance.
Timed get-up-and-go test
Patients were asked to stand up from a standard arm chair,31 32
walk at a safe and comfortable pace for 3 m, and then return to
a sitting position in the chair. The time to complete the test (in
seconds), use of an armrest to get up and sit down, and pain in-
tensity at the site of surgery immediately after the test were re-
corded. This test was administered before surgery and 6 weeks
and 3months after surgery. An important within-patient change
has been estimated to be ∼2.5 s.33 34
Stair test
Patients were asked to ascend and descend one flight of nine
stairs in their usual manner, at a safe and comfortable pace.35 36
Test completion, length of time to complete the test, aids used
(crutches, cane, railing), ascending and descending pattern, and
pain intensity at the site of surgery were recorded. This test was
administered before surgery and 6weeks and 3months after sur-
gery. An important within-patient change has been estimated to
be ∼5.5 s.33 34
Six minute walk test
Patients were asked to walk as far as possible during 6 min, with
the option to stop and rest as needed during the test.37–39 Stan-
dardized encouragement was offered to all patients every 60 s,
because research has shown that encouragement improves per-
formance.40 Total distance walked, test completion, and pain in-
tensity at the site of surgery were recorded. This test was
administered before surgery and at 6 weeks and 3 months after
surgery. An importantwithin-patient change has been estimated
to be ∼62 m.33 34
Sample size estimate
There is a paucity of information available concerning the mag-
nitude of a clinically important between-group difference for per-
formance measures. For this reason, our sample size estimate
was based on the WOMAC physical function scores. Goldsmith
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and colleagues41 have suggested that for self-report measures an
important between-group difference is less than an important
within-patient change. Applying this principle to the WOMAC
physical function scale, we specified an important between-
group difference to be approximately 5 points at 6 weeks and 4
points at 3 months postarthroplasty. The power was set at 0.80,
and the overall type I error probability at 0.05, corrected to
0.0167 because of comparisons at three time points (baseline, 6
weeks, and 3 months). Applying these assumptions yielded an
approximate sample size of 72 subjects per group. Allowing for
an incomplete data percentage of 20%, 92 subjects per group or
184 subjects in total were required.
Statistical analysis
Given a repeated-measures study design, the likelihood of miss-
ing data, correlated errors within individuals, and heterogeneity
among occasion variances (i.e. over time), we applied generalized
estimating equations to test for differences in the timed get-up-
and-go test, the stair test, and the 6 min walk test between the
groups. Dependent variables were the outcome measures as-
sessed at multiple time points (i.e. timed get-up-and-go test,
stair test, and 6 min walk test). The independent variable was
treatment group (pregabalin or placebo), and the covariates
were gender, age, and the before-surgery values for the depend-
ent variable of interest. We applied an autoregressive correlation
structure for cumulativemorphine consumption and an unstruc-
tured correlation structure for all other dependent variables. An
effect was considered statistically significant at P≤0.05, and we
performed intention-to-treat analyses.We did not impute values
when data were missing. All analyses were conducted using
STATA version 13.0 (STATA Corp., College Station, TX, USA).
Results
Recruitment and retention of patients
Patients were recruited between February 2009 and July 2012. The
CONSORT42 flow chart outlining the recruitment and retention of
study patients is shown in Figure 1. Overall, 380 patients were ap-
proached for participation, 173 patients declined participation,
and 207 patients consented to participate in the study, 23 of
whomwere ineligible to participate before randomization as a re-
sult of inappropriate blood work (i.e. creatinine >104). Of the 184
patients randomly assigned to receive pregabalin or placebo, 162
patients remained in the study on POD 4; 77 of 92 patients (83%)
remained in the placebo group, and 85 of 92 (92%) patients re-
mained in the control group on POD 4. The reasons for withdraw-
al or dropout in the placebo group before POD 4 were as follows:
eight patients were removed because of severe adverse effects
(one patient because of severe pain, five patients because of nau-
sea and vomiting, of whomone had concomitant headaches, and
twopatients cited severe dizziness), one patientwas a screen fail-
ure (missed creatinine >104 μmol/L) and ingested the initial study
medications, one patient sustained a femoral fracture on the
morning of POD 4, two patients received a general anaesthetic,
one patient refused to take the study medications on POD 1,
one patient was removed prematurely because of an i.v. PCA
switch, and one was removed by the attending surgeon because
of a low haemoglobin count. The reasons for withdrawal or drop-
out in the pregabalin group before POD 4were as follows: four pa-
tients were removed because of severe adverse effects (one
patient had a vasovagal episode on POD 2, two patients had se-
vere dizziness, and one patient had dizziness and visual
disturbances), one patient was given a general anaesthetic, one
patient was removed by their attending physician because of a
low blood pressure and heart rate, and one patient refused to
take the studymedications on POD2. Threemonths after surgery,
130 patients remained in the study; 60 patients in the placebo
group (17 patients were lost to follow-up), and 70 patients in
the pregabalin group (15 patients were lost to follow-up).
Baseline patient characteristics and clinical variables
There were no significant differences in age, sex, ASA class, BMI,
or any of the psychological and functional measures between pa-
tients in the placebo and pregabalin groups (Table 1).
Performance and patient-report measures; primary 
outcomes
Results of the performance outcome measures (timed get-up-
and-go test, stair test, 6 min walk test, and WOMAC function)
and pain scores across groups at baseline, 6 weeks, and 3months
are presented in Tables 2 and 3. Therewere no statistically signifi-
cant differences between the pregabalin and placebo groups for
any of the performance outcome measures. Furthermore, there
were no clinically significant between-group differences in phys-
ical functioning scores (difference of 5 points on the WOMAC
physical functioning subscale) at 6 weeks and 3 months.
Secondary outcomes
Opioid consumption
Cumulative morphine consumption was significantly lower at 12, 
18, and 24 h after surgery between the pregabalin and placebo 
groups (P<0.05; see Fig. 2).
Pain in hospital
There were no significant differences in pain intensity scores at 
rest or with movement when assessed three times a day until 
POD 4.
Adverse effects
There was a higher incidence of nausea 12 h after THA and of
pruritus on POD 1 in the placebo (10% for both nausea and
pruritus) compared with the pregabalin group (5%; 3.5%, respect-
ively); (P=0.019; P=0.019, respectively) and of vomiting in the
pregabalin group (2%) compared with the placebo group (0%)
1 day after THA (P=0.015). There were no other differences at
any point during hospital stay with respect to nausea, pruritus,
vomiting, sedation, dizziness, or visual disturbances.
One week postdischarge pain diary outcomes
The NRS pain intensity scores were significantly lower in the
pregabalin group compared with the placebo group on the first
7 days after hospital discharge (P<0.05; see Fig. 3).
Adjunctive opioid consumption (Percocet and Tylenol 3) was
also significantly lower in the pregabalin group compared with
the placebo group during the first 7 days after hospital discharge
(P<0.05).
Hospital anxiety and depression scores on postoperative 
day 4 and at 6 weeks and 3 months
There were no significant differences in HADS anxiety scores at
baseline, POD 4, 6 weeks, or 3 months between pregabalin and
placebo groups. The HADS depression score was significantly
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lower in the pregabalin group [3.9 (3.1)] compared with the pla-
cebo group [5.0 (3.8)] on POD 4 (P=0.048). Therewere no significant
differences in depression scores at baseline, 6weeks, or 3months
after THA.
Discussion
Pregabalin has been found to reduce pain and opioid consump-
tionwhen given as an adjunct for surgeries in which general an-
aesthesia is used as the primary anaesthetic modality.43 44 The
present study was designed with the primary aim of examining
whether the addition of pregabalin to a perioperative THA
analgesic regimen (which includes spinal anaesthesia and
perioperative celecoxib) while in hospital and for 1 week
postdischarge improves pain and functional outcomes up to 3
months after surgery. The present study did not find significant
differences between pregabalin and placebo groups in the pri-
mary measures of function (both physical and patient reported)
at 6 weeks or 3 months after THA (Table 2). Furthermore, pain
scores did not differ between groups with respect to each per-
formance-based measure (Table 3). This study found that pa-
tients who received pregabalin used significantly less i.v. PCA
morphine in the first 24 h after surgery (Fig. 2). This finding is
consistent with results from a meta-analysis examining prega-
balin after gynaecological surgery.45 Furthermore, a recent
meta-analysis that pooled data from 24 trials supports the find-
ing that perioperative pregabalin results in a 16% reduction in
analgesic consumption in surgeries associated with pronoci-
ceptive pain (e.g. spine, joint arthroplasty, and amputations).46
The present results do not support the hypothesis of superior
functional performance long term in the pregabalin vs the pla-
cebo group.
Approached
(n=380)
Group I
placebo
(n=92)
Group II
pregabalin
(n=92)
Consented
(n=207)
Randomized
(n=184)
173 Patients refused
participation 
POD4:
(n=85)
POD4:
(n=77)
6 weeks:
(n=85)
6 weeks:
(n=77)
3 months:
(n=60)
3 months:
(n=70)
23 Patients were ineligible due
to exclusion criterion 
17 lost to follow-up 15 lost to follow-up
4 pts-removed due to severe side effects,
such as vomiting, dizziness, visual
disturbances, pain, or nausea.
1 pt-was given GA
1 pt-removed by surgeon due to low BP and
HR
1 pt-refused to take study’s medications. 
Excluded prior to POD 4:8 pts-removed due to severe side effects, such
as vomiting, dizziness, pain, or nausea.
1 pt-removed due to screening failure
1 pt-removed due to femur fracture on POD4
2 pts-were given GA
1 pt-refused to take study’s medications
1 pt-PCA switch
1 pt-had low Hgb
Excluded prior to POD 4:
Fig 1 Patient enrolment and study flow. BP, blood pressure; GA, general anaesthesia; Hgb, haemoglobin; HR, heart rate; PCA, patient-controlled analgesia; POD 4, 
postoperative day 4; pt, patient.
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There continues to be a significant gap in the care of patients
after discharge from hospital.47 Often, patients are sent home
after surgery without multimodal analgesic regimens that are
similar to hospital-based regimens. Most commonly, patients
are prescribed a single opioid-basedmedication.48 Therefore, pa-
tients unable to tolerate opioid-based medications are left to
struggle with moderate-to-severe postoperative pain. We de-
signed this trial to assess the postdischarge time period and
the pain relief afforded to patients during the first week after hos-
pital dischargewhile the studymedications were continued. The
results showed that patients receiving pregabalin daily for 1week
after hospital discharge had lower numerical rating scores every
day that the pain was assessed when compared with patients
who were given placebo (Fig. 3). Patients in the pregabalin
group also used less adjunctive opioid-basedmedications (Perco-
cet, Tylenol 3) during the 1 week after discharge (P<0.05).
Inadequatelymanaged acute pain is a key factor in poor func-
tioning after surgery,49 and while postdischarge monitoring of
pain remains under-reported there is evidence to suggest that
the management of acute pain after surgery is suboptimal,
with pain intensifying after discharge from hospital.4 A recent
systematic review of persistent neuropathic pain after surgery
has identified that persistent neuropathic pain is a long-term
problem for 6% of patients after hip and knee arthroplasty.50 At
the present time, there is a paucity of literature regarding safe
and effectivemanagement of postoperative pain as patients tran-
sition from the hospital to home and community. Our results
demonstrate that administeration of pregabalin during the first
7 days after hospital discharge reduced pain intensity (Fig. 3)
and the need for supplemental opioid analgesic medication
and is safe. The addition of the anticonvulsant medications (i.e.
gabapentin and pregabalin, α2δ subunit voltage-dependent cal-
cium channel blockers) may prove to be a useful tool in the post-
discharge time period with patients struggling from prolonged
moderate-to-severe acute postsurgical pain.51 In a recent system-
atic review, even though results between the studies included
were heterogeneous at 3 month follow-up, pregabalin was pro-
posed to have an effect with respect to modifying postsurgical
pain trajectories and reducing the development of chronic post-
surgical pain.52 However, in light of a recent publication demon-
strating that several cohorts of patients did not experience the
preventive effect for pregabalin on chronic post surgical pain
(CPSP)53 and the evidence we present herein, this conclusion
needs to be reassessed.
Patients receiving pregabalin had lower in-hospital depres-
sion scores on POD 4 compared with placebo-treated patients.
However self-report measures of anxiety, depressive symptoms,
and pain disability at all other time points throughout the trial
were unaffected by pregabalin administration. There was a re-
duction in pain disability index scores from baseline to 3months
in both groups, which demonstrates the effectiveness of THA in
Table 2 Performance and patient-reported physical function measures. *Negative difference favours pregabalin group. †Positive difference 
favours pregabalin group. The timed up-and-go and stair tests are scored based on the number of seconds associated with completing the 
task. The 6 min walk test is scored as the distance covered (in metres). The WOMAC total scores range from 0 to 68 for the physical function 
subscale, with higher scores indicating worse pain, stiffness, or physical limitations. Postoperative day 4 data are not reported here because 
a significant proportion of patients were unable to complete functional outcome measures at this time point. CI, confidence interval; 
WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index
Test Placebo group Pregabalin group Adjusted
Unadjusted Unadjusted difference
n mean () n mean () (95% CI)
Timed up-and-go (s)*
Before surgery 78 12.6 (0.5) 83 13.1 (0.7) 0.6 (−1.0, 2.2)
6 weeks 67 10.8 (0.4) 81 11.5 (0.5) 0.8 (−0.8, 2.5)
3 months 54 9.1 (0.4) 66 9.2 (0.4) 0.1 (−1.7, 2.0)
Stair test (s)*
Before surgery 78 18.9 (1.4 84 18.9 (1.0) −0.2 (−3.5, 3.2)
6 weeks 67 19.2 (1.3) 78 19.6 (1.3) 0.4 (−3.21, 3.9)
3 months 54 12.2 (0.5) 66 12.3 (0.7) −0.2 (−4.1, 3.6)
6 min walk (m)†
Before surgery 71 376 (14) 76 366 (14) −10 (−49, 28)
6 weeks 64 394 (12) 80 392 (11) −4 (−43, 35)
3 months 52 476 (11) 66 475 (12) 2 (−45, 40)
WOMAC function (0–68)*
Before surgery 77 32.8 (1.2) 83 34.9 (1.3) 2.2 (−1.4, 5.9)
6 weeks 54 14.4 (1.4) 59 12.4 (1.3) −1.4 (−5.8, 2.9)
3 months 53 8.0 (1.0) 65 9.0 (1.1) 1.2 (−3.0, 5.5)
Table 1 Patient characteristics and baseline self-report 
characteristics. All data are presented as the mean () except 
sex and ASA class, which are frequency. WOMAC, Western 
Ontario and McMaster Universities Osteoarthritis Index
Characteristic Placebo
group
Pregabalin
group
Age (yr) 60.1 (8.8) 60.2 (9.5)
Sex (male/female) 41/38 41/42
BMI (kg m−2) 28.7 (4.3) 29.1 (6.9)
ASA class
I 4 8
II 20 25
III 0 2
WOMAC pain (0–10) 9.0 (3.4) 9.6 (3.5)
WOMAC stiffness (0–8) 4.3 (1.7) 4.4 (1.6)
WOMAC physical function (0–68) 32.8 (10.1) 34.9 (11.8)
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reducing pain disability. Studies have shown that high levels of
preoperative pain and anxiety are independent risk factors for
acute postsurgical pain54 and are associated with the develop-
ment of chronic postsurgical pain after knee arthroplasty sur-
gery.55 Our group also demonstrated that gabapentin 1200 mg,
when administered to highly anxious females (i.e. baseline anx-
iety >5/10) undergoing major surgery, significantly reduced pre-
operative anxiety and pain catastrophizing before major
surgery.56 A recent systematic review has also found that pain
catastrophizing predicts CPSP after total knee arthroplasty.57
This emerging literature suggests that patients should be
screened before surgery for psychological vulnerabilities, and
based on the results, psychological interventions, in addition to
multimodal preventive analgesic strategies such as the ones im-
plemented in this trial, should become amainstay for periopera-
tive postsurgical care.51
This is the first study to compare the efficacy of pregabalin vs
placebo for recovery of physical function at three time points
(baseline, 6 weeks, and 3 months) for patients undergoing total
hip arthroplasty. Although negative for such outcomes, a reduc-
tion in cumulative 24 h opioid consumption and superior pain re-
lief for 1 week postdischargewas evident. The present results are
specific to our multimodal analgesic regimen (i.e. spinal anaes-
thesia and celecoxib) and cannot be generalized to the same sur-
gery with alternative perioperative pain regimens or other
surgeries performed under general anaesthesia. The major limi-
tation to the present study is the dropout rate at the 3month time
point. We examined baseline differences between patients who
did vs did not complete the 3 month follow-up. The results
showed no significant differences between completers vs non-
completers in terms of baseline functional outcomes, pain, de-
pression, anxiety, and pain interference (P-values >0.05). Given
that there was no difference in physical function or pain at 6
weeks post-THA, it is unlikely that this would have been different
at 3 months.
In conclusion, an in-hospital regimen of pregabalin (150 mg
before surgery followed by 75 mg BID), co-administered with cel-
ecoxib, decreased immediate postoperative analgesic require-
ments. Patients discharged with pregabalin (75 mg BID) for 1
Table 3 Pain ratings. Pain scores for the timed up-and-go, stair test, and 6 min walk test are based on an 11-point numerical rating scale for
pain (0=‘no pain’ and 10=‘worst pain possible pain’). The WOMAC pain score ranges from 0 to 20 for the pain subscale
Test Placebo group Pregabalin group
n Median
(first, third quartiles)
n Median
(first, third quartiles)
Timed up-and-go (/10)
Before surgery 79 4 (2, 6) 83 5 (3, 7)
6 weeks 69 0 (0, 1) 82 0 (0, 1)
3 months 54 0 (0, 0) 65 0 (0, 0)
Stair test (/10)
Before surgery 77 2 (4, 6) 83 5, (2, 7)
6 weeks 68 0 (0, 2) 81 0 (0, 1)
3 months 54 0 (0, 1) 65 0 (0, 1)
6 min walk (/10)
Before surgery 75 5 (3, 7) 80 5 (3, 7)
6 weeks 67 1 (0, 2) 82 1 (0, 2)
3 months 53 0 (0, 1) 65 0 (0, 1)
WOMAC pain (/20)
Before surgery 79 9 (7, 12) 83 10 (8,12)
6 weeks 75 3 (1, 5) 82 2 (1, 4)
3 months 53 1 (0, 3) 69 1 (0, 3)
60 P=0.402 P=0.021 P=0.004 P<0.001
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week after surgery had better pain control while at home and a
reduced need for supplemental opioid medications. The prega-
balin regimen did not improve pain or physical function 6 weeks
or 3 months after surgery. Specific subpopulations of patients, ex-
cluded from the present study, may have had significant benefits
from the opioid-sparing effects of pregabalin in the perioperative
period. Future studies should focus on the efficacy of perioperative
pregabalin for patients with obstructive sleep apnoea or chronic
painand those taking opioidmedications, because these subpopu-
lations might benefit even more with respect to the pregabalin-
induced opioid-sparing effect and the reduction in postdischarge
pain we observed in the present study.
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